By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Otsuka America Pharmaceutical, Inc. 

2440 Research Boulevard

Rockville  Maryland  20850  U.S.A.
Phone: 301-990-0030 Fax: 301-212-8620

Otsuka is a successful, global group of affiliated companies that discovers, develops and markets innovative products. In the U.S., Otsuka is hard at work investigating potential new treatments, with numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal and central nervous systems, and to treat cancer and ophthalmic disorders. Our pharmaceutical products include ABILIFY® (aripiprazole) Tablets and intramuscular injection, IV BUSULFEX® (busulfan) Injection and PLETAL® (cilostazol) Tablets, although we no longer actively market PLETAL. We also have the BreathTek™ Urea Breath Test for H. pylori. We have numerous additional products in our pipeline that are currently under development. We are highly diversified, with pharmaceutical as well as consumer products such as Crystal Geyser Water, NatureMade® Vitamins, Ridge Wines, and diagnostic equipment.

Please visit our website at for more information.

Key Statistics

Ownership: Subsidiary

Web Site: Otsuka America Pharmaceutical, Inc.


Company News
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S (LUN.CO) Release: U.S. FDA Accepts For Review Supplemental New Drug Application For Deltoid Administration Of Abilify Maintena® (Aripiprazole) Extended-Release Injectable Suspension 12/15/2014 10:13:44 AM
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S (LUN.CO) Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia 11/3/2014 10:57:38 AM
European Medicines Agency Accepts Otsuka America Pharmaceutical, Inc.'s Marketing Authorisation Application (MAA) For Tolvaptan, An Investigational Compound For Autosomal Dominant Polycystic Kidney Disease (ADPKD) 12/27/2013 7:38:51 AM
Bristol-Myers Squibb Company (BMY) and Otsuka America Pharmaceutical, Inc. Release: Four-Year Data From Phase 3 DASISION Trial Comparing Sprycel® (dasatinib) To Imatinib In First-Line Treatment Of Adults With Ph+ CP-CML Presented At Annual Meeting Of The American Society of Hematology 12/10/2013 6:56:26 AM
Almac Group Receives Appreciation Award From Otsuka America Pharmaceutical, Inc. 7/31/2013 9:54:30 AM
Almac Group Receives Appreciation Award From Otsuka America Pharmaceutical, Inc. 7/31/2013 7:11:20 AM
FDA Warns of Liver Injury Risk With Otsuka America Pharmaceutical, Inc.'s Tolvaptan 1/25/2013 8:40:49 AM
Otsuka America Pharmaceutical, Inc. Opens First Office in Canada 10/4/2010 12:31:57 PM
UK's National Institute for Clinical Excellence (NICE) Wants More Data on Bristol-Myers Squibb Company (BMY) And Otsuka America Pharmaceutical, Inc. Schizophrenia Drug Abilify 9/10/2010 8:00:19 AM
Bristol-Myers Squibb Company (BMY) Announces Extension of U.S. Agreement for ABILIFY(R) and Establishment of an Oncology Collaboration with Otsuka America Pharmaceutical, Inc. 4/6/2009 9:53:35 AM